Showing results (191-200 of 495) with videos related to
Sort By:
Pageof 50
Health Affairs (Project Hope)|February 5, 2014
Quantifying The Food And Drug Administration's rulemaking delays highlights the need for transparencyThomas J Hwang, Jerry Avorn, Daniel Carpenter, et al.Clinical Pharmacology and Therapeutics|June 19, 2021
Cost to Medicare of Delayed Adalimumab Biosimilar AvailabilityChangWon C Lee, Mehdi Najafzadeh, Aaron S Kesselheim, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized TrialsBishal Gyawali, Elvira D'Andrea, Jessica M Franklin, et al.The Lancet. Infectious Diseases|June 6, 2020
Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984-2018: an evaluation of Food and Drug Administration flexibilitiesJonathan J Darrow, Mehdi Najafzadeh, Kristina Stefanini, et al.JAMA Dermatology|April 16, 2025
Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the USBenjamin N Rome, Jihye Han, Helen Mooney, et al.JAMA Internal Medicine|October 5, 2017
Strategies That Delay Market Entry of Generic DrugsKerstin Noëlle Vokinger, Aaron S Kesselheim, Jerry Avorn, et al.Health Affairs (Project Hope)|January 20, 2017
Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug MakersAaron S Kesselheim, Benjamin N Rome, Ameet Sarpatwari, et al.BMJ (Clinical Research Ed.)|November 26, 2014
Innovative research methods for studying treatments for rare diseases: methodological reviewJoshua J Gagne, Lauren Thompson, Kelly O'Keefe, et al.Eclinicalmedicine|March 8, 2021
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancerBishal Gyawali, Elvira D'Andrea, Jessica M Franklin, et al.Health Economics|January 13, 2022
Biosimilar competition: Early learningRichard G Frank, Mahnum Shahzad, Aaron S Kesselheim, et al.Pageof 50